Doxifluridine
Structural formula | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | ||||||||||||||||
Non-proprietary name | Doxifluridine | |||||||||||||||
other names |
|
|||||||||||||||
Molecular formula | C 9 H 11 FN 2 O 5 | |||||||||||||||
External identifiers / databases | ||||||||||||||||
|
||||||||||||||||
Drug information | ||||||||||||||||
ATC code | ||||||||||||||||
Drug class | ||||||||||||||||
properties | ||||||||||||||||
Molar mass | 246.19 g mol −1 | |||||||||||||||
Physical state |
firmly |
|||||||||||||||
Melting point |
190 ° C |
|||||||||||||||
safety instructions | ||||||||||||||||
|
||||||||||||||||
Toxicological data | ||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Doxifluridine is an analogue of the nucleoside uridine and a drug that is used as a cytostatic in chemotherapy .
Pharmacokinetics
Doxifluridine is metabolized to 5-fluorouracil and 5,6-dihydrofluoruracil. Oral bioavailability is 34–47%.
Side effects
Doxifluridine is cell damaging. It is carcinogenic (it can cause cancer), mutagenic (can cause hereditary damage), and teratogenic (can cause harm to the unborn child). Depending on the dose, diarrhea, nausea, vomiting, loss of appetite, irritation of the mucous membranes and blood changes can occur.
Individual evidence
- ↑ a b Entry on doxifluridine in the ChemIDplus database of the United States National Library of Medicine (NLM) .
- ↑ a b Doxifluridine data sheet from Sigma-Aldrich , accessed on February 3, 2011 ( PDF ).